Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Medical - Care Facilities

Healthcare
$20.95 -0.76%

-$0.18 today

Market cap
$11.26B
Beta
0.81
P/E (TTM)
11.9
EPS (TTM)
$3.43
Dividend yield
3.65%
52W Low $20.02High $28.87

Volume 1.92M

Average 0.72M

FMS Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Fresenius Medical Care AG & Co. KGaANYSE: FMS

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income growth accelerates

Q2 FY2026 operating income of €465.86M rose 18.1% year over year, ahead of the +15.5% change in trailing-twelve-month operating income. Sequentially, it rose 24.0% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Operating income amounted to 9.3% of revenue in FY2025, up 1.7 pp from a year earlier.
  • Operating income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 9 analysts of €1.91B (+4.4%) for the fiscal year ending Dec 2026, a slowdown from the +24.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€465.86M+24.0% QoQ
Last fiscal yearDec 2025
€1.83B+24.5% YoY
LTMJun 2026
€1.89B+15.5% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.1%-3.5%-21.6 pp
1 year+24.5%+4.4%-20.1 pp
3-year CAGR+6.5%+4.6%-1.9 pp
5-year CAGR+8.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

EUR · from the income statement

Latest · FY2025
1.83B EUR
Year-over-year change
+24.5%
4-year CAGR
-0.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How FMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.5% is the 2nd highest of 4, against a peer median of +1.6%.
  • Operating income amounts to 9.7% of revenue for FMS, versus a peer median of 15.1%.
FMS Competitors
Operating Income for FMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DVADaVita Inc.LTM Jun 2026$2.11B USD+1.6%+14.5%15.1%
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€1.89B EUR+15.5%+6.5%9.7%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$5.29M USD+124.0%—2.3%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$133.49M USD-46.5%—20.5%
Peer median (excluding FMS) —+1.6%+14.5%15.1%

Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.62B19.4B19.45B19.34B19.63B
Cost of Revenue12.85B14.5B14.53B14.58B14.6B
Gross Profit4.77B4.89B4.93B4.76B5.03B
Gross Margin27.1%25.2%25.3%24.6%25.6%
Research & Development220.78M228.62M231.97M183.49M157.98M
Selling, General & Admin2.77B3.17B3.2B3.14B3.03B
Operating Expenses2.92B3.38B3.56B3.29B3.2B
Depreciation & Amortization1.62B1.84B1.75B1.74B1.5B
EBITDA3.55B3.42B3.21B3.21B3.4B
EBITDA Margin20.1%17.6%16.5%16.6%17.3%
Operating Income1.85B1.51B1.37B1.47B1.83B
Operating Margin10.5%7.8%7.0%7.6%9.3%
Interest Income73.17M67.66M88.22M71.58M69.61M
Interest Expense353.6M360.14M424.64M407.04M384.41M
Other Income / Expenses(280.43M)(292.48M)(336.42M)(410.45M)(314.59M)
Income Before Tax1.57B1.22B1.03B1.06B1.51B
Pre-Tax Margin8.9%6.3%5.3%5.5%7.7%
Income Tax Expense352.83M324.95M300.56M316.06M320.97M
Net Income969.31M673.41M499M537.91M978.37M
Net Margin5.5%3.5%2.6%2.8%5.0%
EPS (Basic)0.830.570.850.921.68
EPS (Diluted)0.830.570.850.921.68
Weighted Avg Shares1.17B1.17B586.83M586.83M582.38M
Weighted Avg Shares (Diluted)1.17B1.17B586.83M586.83M582.38M

Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.